• Episode 47: ESMO 2026 Commentary: Prostate Cancer
    Nov 5 2026

    Rounding out their three-part coverage from the ESMO 2026 Congress in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis welcome special guest Dr. Sébastien Hotte to explore the latest developments in prostate cancer research and treatment.

    The conversation begins with findings from the DASL-HiCaP trial, examining the role of darolutamide alongside androgen deprivation therapy (ADT) and radiation therapy in very high-risk localized prostate cancer. The discussion also revisits the PROTEUS trial, highlighting new data from its surgical substudy, evolving approaches to treatment intensification, and the importance of multidisciplinary collaboration in optimizing patient care.

    Turning to emerging therapies, the panel explores promising early findings involving RIPTAC molecules and their novel mechanism of action. They also review updated evidence from PEACE-1 andquality-of-life findings from the PR.21 trial, considering how these advances may shape treatment decisions in metastatic prostate cancer.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.

    Mostra di più Mostra meno
    41 min
  • Episode 46: ESMO 2026 Commentary: Kidney Cancer
    Nov 5 2026

    Continuing their coverage from ESMO 2026 in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis turn their attention to kidney cancer, highlighting the latest research and emerging approaches to the treatment of renal cell carcinoma (RCC).

    The discussion begins with long-term follow-up data from KEYNOTE-564, examining the sustained benefits of adjuvant pembrolizumab and the importance of balancing treatment outcomes with patient experience. They also explore findings from the PE-PE trial, considering the potential role of immunotherapy alongside metastasis-directed treatment in oligometastatic RCC.

    Turning to advanced disease, Dr. Lalani and Dr. Wallis review the LITESPARK-012 and LITESPARK-011 trials, discussing treatment combinations, progression-free and overall survival outcomes, and the challenges of balancing efficacy with toxicity. The conversation also highlights emerging research onbispecific T-cell engagers, including early findings from the XmAb819 trial, offering a glimpse into the future of kidney cancer treatment.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.

    Mostra di più Mostra meno
    30 min
  • Episode 45: ESMO 2026 Commentary: Bladder Cancer
    Nov 5 2026

    Recorded in Madrid at ESMO 2026, Dr. Aly-Khan Lalani and Dr. Christopher Wallis kick off a three-part series highlighting the latest advances in GU cancer care, beginning with bladder cancer.

    With perioperative treatment for muscle-invasive bladder cancer evolving rapidly, Dr. Lalani and Dr. Wallis revisit the NIAGARA trial alongside emerging findings from ENERGIZE and KEYNOTE-866, comparing key trial outcomes and exploring their potential implications for clinical practice.

    The conversation also explores emerging ctDNA biomarker data from KEYNOTE-B15/EV-304, new findings from KEYNOTE-905/EV-303, and the highly anticipated VOLGA trial. Dr. Lalani and Dr. Wallis examine the evolving roles of antibody-drug conjugates and immunotherapy, weighing treatment efficacy against potential toxicity, and highlighting the questions that remain around optimizing perioperative care.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.

    Mostra di più Mostra meno
    40 min
  • Episode 44: Multidisciplinary Care and Treatment Optimization in Localized Prostate Cancer
    Oct 1 2026

    Dr. Lalani and Dr. Wallis kick off the new academic year with special guest Dr. Alejandro Berlin, a clinician-scientist and radiation oncologist at Princess Margaret Cancer Centre.

    This episode highlights multidisciplinary care and treatment optimization in localized prostate cancer, focusing on how specialists collaborate to help patients navigate treatment options and their potential quality-of-life impacts. The conversation also examines the evolution of systemic therapy in high-risk disease, including considerations around the optimal duration of ADT and the integration of ARPIs.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.

    Mostra di più Mostra meno
    41 min
  • Episode 43: ASCO Annual Meeting 2026 Commentary: Bladder Cancer
    Jun 5 2026

    Dr. Aly-Khan Lalani and Dr. Chris Wallis dive into the latest bladder cancer breakthroughs, starting with crucial long-term updates from the landmark EV-302 trial. They share encouraging survival data for patients, while exploring which treatments work best if the cancer eventually progresses. The doctors also discuss the future of localized disease, reviewing strategies from the POTOMAC and SAKK trials. By highlighting a range of advanced monitoring tools, they map out how modern care is helping patients safely avoid major surgery while maintaining excellent disease control.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.

    Mostra di più Mostra meno
    30 min
  • Episode 42: ASCO Annual Meeting 2026 Commentary: Kidney Cancer
    Jun 5 2026

    Dr. Aly-Khan Lalani and Dr. Chris Wallis discuss how new data from the RAMPART trial strengthens the argument for administering immune-boosting therapies to patients after surgery. This episode also touches on the human side of cancer care, exploring new ways to measure patient side effects and reduce post-treatment regret through improved counseling. The doctors finish the conversation by highlighting a promising new combination of repurposed drugs that is offering renewed hope to young patients fighting Renal Medullary Carcinoma.

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.


    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    Mostra di più Mostra meno
    25 min
  • Episode 41: ASCO Annual Meeting 2026 Commentary: Prostate Cancer
    Jun 5 2026

    Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial.

    Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review of sequencing chemotherapy and radioligand therapy in the PLUDO trial, this episode provides an excellent overview of the prostate cancer landscape presented at ASCO 2026.

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.


    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    Mostra di più Mostra meno
    35 min
  • Episode 40: Bladder Cancer Masterclass with Dr. Girish Kulkarni (Part 2)
    May 11 2026

    In Part 2 of the Bladder Cancer Awareness Month series, Dr. Kulkarni, Dr. Lalani and Dr. Wallis examine a "systemic therapy first" approach. Using a real-world patient scenario, the doctors break down the latest clinical trial data and discuss how the surge in neoadjuvant therapy is reshaping everyday decision-making.

    The conversation also tackles the unique challenges of Upper Tract Urothelial Carcinoma. From evidence gaps in upper tract care to the complexities of trial design, this episode offers a forward-looking map of the evolving urothelial cancer landscape.

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.


    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    Mostra di più Mostra meno
    22 min